To assess the efficacy, safety and cost effectiveness of clopidogrel over aspirin with regard to renal function, platelet aggregation and C-Reactive protein (as an inflammatory marker) in chronic kidney disease patients. This evidence concerns the gene CRP and chronic kidney disease.